Clinical Trial Update: An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin [Phase 2]

View source ↗

Summary

Phase 2 open-label study of ABI-007 (Abraxane) plus carboplatin in advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: Celgene | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED